Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
8 Results for "
PROTAC Bcl2 degrader-1
" in MedChemExpress (MCE) Product Catalog:
Products (8)
8 Results for "PROTAC Bcl2 degrader-1" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which potently and selectively induces the degradation of Bcl-2 (IC50, 4.94 μM; DC50, 3.0 μM) and Mcl-1 (IC50, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1 .
1
1 Cited Publications
Target:
Research Areas:
PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC) based on Cereblon ligand, is a potently and selectively Mcl-1 (Bcl-2 family member) inhibitor with an IC50 of 0.78 μM. PROTAC Mcl1 degrader-1 inhibits Bcl-2 with an IC50 of 0.54 μM .
Cat. No.: HY-131188
CAS No.: 2450351-07-0
Target:
Research Areas:
PROTAC Bcl-xL degrader-1 is a PROTAC that comprises a Bcl-xL (Bcl-2 family member) ligand binding group, a linker and an IAP E3 ligases binding group. PROTAC Bcl-xL degrader-1 is a potent Bcl-xL degrader, and shows toxicity for human platelets and MyLa 1929 cells with IC50 values of 62 nM and 8.5 μM, respectively .
Cat. No.: HY-178176
Research Areas:
PROTAC CB1R Degrader-1 is a potent and selective CB1R PROTAC degrader that exploits the ubiquitin-proteasome system (UPS) achieving a DC50 of 3.37 μM in MCF-7 cells and showing no impact on CB2R. PROTAC CB1R Degrader-1 reduces CB1R-associated downstream signaling (p-AKT, p-ERK, BCL2, and MCM5), thereby inhibiting breast cancer cell proliferation and inducing apoptosis. PROTAC CB1R Degrader-1 can be used for breast cancer research .
Cat. No.: HY-178066
Target:
Research Areas:
PROTAC BCL-xL/BCL-w Degrader 1 is a selective BCL-xL/BCL-w PROTAC degrader. PROTAC BCL-xL/BCL-w Degrader 1 promotes ubiquitination and degradation of BCL-xL and BCL-w, without affecting BCL-2. PROTAC BCL-xL/BCL-w Degrader 1 can be used for the research of Hodgkin lymphoma .
Cat. No.: HY-176421
CAS No.: 3070438-85-3
Target:
PROTACs PI3K Apoptosis Akt Bcl-2 Family Caspase P-glycoprotein
Research Areas:
PROTAC PI3K/110β degrader-1 is a VHL-recruiting PROTAC degrader targeting PI3K/110β, with DC50 values of 0.416 μM (MCF-7) and 19.66 μM (A549), respectively. PROTAC PI3K/110β degrader-1 recruits VHL to induce proteasomal degradation of PI3K/110β. It activates endoplasmic reticulum stress (ERS)-mediated mitochondrial apoptosis via the PERK/ATF4/CHOP unfolded protein response (UPR) pathway, downregulates p-AKT and Bcl-2, upregulates Bax, cleaved-caspase-9 and cleaved-caspase-3, inhibits the expression and activity of P-gp, and exerts synergistic anti-tumor effects with Doxorubicin (Adriamycin, ADM) (HY-15142A) and Cisplatin (DDP) (HY-17394). PROTAC PI3K/110β degrader-1 can be used in research related to multidrug-resistant cancers .
Cat. No.: HY-158551
CAS No.: 3034200-49-9
Target:
Research Areas:
PROTAC Bcl-2/Bcl-xL Degrader-1 is a Bcl-2/Bcl-xL PROTAC degrader with a DC50 of 11.28 nM against Bcl-xL. PROTAC Bcl-2/Bcl-xL Degrader-1 promotes ubiquitination and degradation of Bcl-2/Bcl-xL. It exhibits anticancer activity against acute lymphoblastic leukemia. PROTAC Bcl-2/Bcl-xL Degrader-1 can be used in the research of BCL-2-mediated or BCL-2-dependent diseases .
Cat. No.: HY-158677
CAS No.: 3034202-16-6
Research Areas:
Bcl-2/Bcl-xL ligand 1 is a Bcl-2/Bcl-xL ligand that can serve as a PROTAC target protein ligand for studies related to PROTAC synthesis, such as the synthesis of PROTAC Bcl-2/Bcl-xL Degrader-1 (HY-158551) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
